Corporate Profile

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.
Featured Documents
3/2/20
March 2020 Corporate Presentation

Share Price

Price
Change (%)  (%)
Volume
Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events
There are currently no events scheduled.
Recent News
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020
5/4/20
SAN DIEGO , May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the
Read More →
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium
4/13/20
SAN DIEGO , April 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing
Read More →
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany
4/7/20
SAN DIEGO , April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing
Read More →